Page 2 - Daniel Gruskin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Published: May 21, 2021 By Alex Keown Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers.  AavantiBio – Jessie Hanrahan was named chief regulatory officer of AavantiBio. Hanrahan will oversee global regulatory affairs for AavantiBio’s diversified pipeline of gene therapy programs targeting rare diseases with significant unmet medical needs. Most recently, she was Vice President of Regulatory Science at bluebird bio, Inc. Prior to bluebird bio, Hanrahan held positions of increasing responsibility at Genzyme Corp. where she...

LogicBio Announces Presentation of Retrospective Study of Disease Course in Pediatric Patients with Severe Methylmalonic Acidemia - Data presented at ACMG meeting evaluate disease progression in non-transplanted patients and children receiving liver transplantation News provided by Share this article Share this article LEXINGTON, Mass., May 3, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced results f...

LogicBio announces clinical and corporate updates DJ LogicBio announces clinical and corporate updates Arix Bioscience PLC (ARIX) LogicBio announces clinical and corporate updates 27-Apr-2021 / 14:00 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. =---------------------------------------------------------------------------------------------------------------------- Arix Bioscience plc LogicBio announces clinical and corporate updates - First patient in Phase I/II SUNRISE trial expected...

LogicBio Therapeutics Announces Clinical and Corporate Updates - First patient for Phase I/II SUNRISE trial expected to be enrolled by mid-year 2021 - Company also entered into strategic collaboration with CANbridge Pharmaceuticals and research partnership with Daiichi Sankyo News provided by Share this article Share this article LEXINGTON, Mass., April 27, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today annou...